Apollomics (NASDAQ:APLM) CFO Peter Kuan-How Lin Buys 26,667 Shares

Apollomics Inc. (NASDAQ:APLM) CFO Peter Kuan-How Lin acquired 26,667 shares of Apollomics stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $15.00 per share, with a total value of $400,005.00. Following the completion of the transaction, the chief financial officer owned 48,979 shares of the company’s stock, valued at approximately $734,685. This trade represents a 119.52% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Apollomics Stock Performance

APLM opened at $23.36 on Tuesday. Apollomics Inc. has a 12 month low of $3.66 and a 12 month high of $42.12. The stock’s 50 day moving average price is $18.24 and its 200 day moving average price is $17.30.

Hedge Funds Weigh In On Apollomics

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC bought a new stake in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.